Clinicians now have a wide variety of immunoassay and nucleic acid tests available to them to diagnose the many types of hepatitis viruses and manage the resulting infections, some of which are chronic and require lifelong management. Consequently, knowing which test to select in certain situations can be confusing. From test selection to result interpretation to monitoring therapy, lab leaders can play a much greater role in helping their institutions improve the processes that lead to earlier detection of the hepatitis viruses and better patient management. In the case of hepatitis C virus (HCV), new therapies are now available that are prolonging the lives of HCV patients, making it more important
than ever to identify and treat those with the disease. During this webcast, viewers will learn how
lab leaders can help improve the processes used to identify and manage patients with hepatitis C infections, how to consult with clinicians about what the results of hepatitis C and liver function tests mean clinically, partner with other healthcare providers to streamline testing and patient management protocols, and institute appropriate testing strategies for early detection.
Speaker Presentation Description
Anthony Killeen, MD, PhD, Professor, Vice Chair for Clinical Affairs and Director of Clinical Pathology, University of Minnesota, Minneapolis, MN